- Designation offers potential hope of new treatment options for people with Fragile X and their families.
About Fragile X Syndrome (FXS)
About Tetra Therapeutics
About Shionogi & Co. Ltd.
Shionogi & Co., Ltd. is a 145-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.
For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en.
Forward-Looking Statements
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html
SEU Press Office: pressoffice@shionogi.eu
References:
1. Cleveland Clinic. Fragile X Syndrome: Diagnosis, Symptoms & Treatment. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/5476-fragile-x-syndrome.
2. European Commission. Rare diseases. European Commission. https://health.ec.europa.eu/european-reference-networks/rare-diseases_en.
3. Duy PQ, Budimirovic DB. Fragile X Syndrome: Lessons Learned from the Most Translated Neurodevelopmental Disorder in Clinical Trials. Transl Neurosci. 2017 Mar 11;8:7-8. doi: 10.1515/tnsci-2017-0002. PMID: 28400977; PMCID: PMC5382936.
4. Centers for Disease Control and Prevention. Fragile X: Learning What Families Need. CDC. https://www.cdc.gov/ncbddd/fxs/features/learning-what-families-need.html.
5. Alusi G, Berry-Kravis E, Nelson D, Orefice LL, Booker SA. Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A. ACS Chem Neurosci. 2022 Dec 21;13(24):3544-3546. doi: 10.1021/acschemneuro.2c00674. Epub 2022 Dec 7. PMID: 36475635; PMCID: PMC9782331.
6. Berry-Kravis, E.M., Harnett, M.D., Reines, S.A. et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat Med 27, 862–870 (2021). https://doi.org/10.1038/s41591-021-01321-w.
7. Ciaccio, C., Fontana, L., Milani, D., et al. Fragile X syndrome: A review of clinical and molecular diagnoses. Ital J Pediatr. 19, 43(1): 39 (2017). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395755/.